UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor

Nature communications, 2022-06, Vol.13 (1), p.3127-3127, Article 3127

2022

Volltextzugriff (PDF)

Intraductal xenografts show lobular carcinoma cells rely on their own extracellular matrix and LOXL1

EMBO molecular medicine, 2021-03, Vol.13 (3), p.e13180-n/a

2021

Volltextzugriff (PDF)

Cytokine storm complicated by cardiogenic shock induced by anti-HER2 therapies

Journal for immunotherapy of cancer, 2023-06, Vol.11 (6), p.e006942

2023

Volltextzugriff (PDF)

Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer

Pharmaceutics, 2022-06, Vol.14 (7), p.1317

2022

Volltextzugriff (PDF)

Pretreatment Thrombocytosis as a Prognostic Factor in Metastatic Breast Cancer

International Journal of Breast Cancer, 2013-01, Vol.2013 (2013), p.64-69

2013

Volltextzugriff (PDF)

Male breast cancer: a lesser-known battle

Revue médicale suisse, 2024-05, Vol.20 (874), p.968

2024

Volltextzugriff (PDF)

Cancer du sein chez l’homme : un combat méconnu

Revue médicale suisse, 2024, Vol.20 (874), p.968-972

2024

Volltextzugriff (PDF)

Cancer du sein chez l’homme : un combat méconnu

Revue médicale suisse, 2024, Vol.20 (874), p.968-972

2024

Volltextzugriff (PDF)

The Future of ER+/HER2− Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors

Anticancer research, 2020-09, Vol.40 (9), p.4829-4841

2020

Volltextzugriff (PDF)

Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies

Anticancer research, 2023-03, Vol.43 (3), p.967-981

2023

Volltextzugriff (PDF)

Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond

Expert review of anticancer therapy, 2024-04, Vol.24 (3-4), p.117-135

2024

Volltextzugriff (PDF)

Peroxisome Proliferator-Activated Receptor Gamma and Regulations by the Ubiquitin-Proteasome System in Pancreatic Cancer

PPAR Research, 2012, Vol.2012 (2012), p.290-302

2012

Volltextzugriff (PDF)

Plötzlich hörte sie Stimmen

Swiss medical forum, 2020-02

2020

Volltextzugriff (PDF)

A Systematic Review and Meta-analysis of the Combination of Vinorelbine and Lapatinib in Patients With Her2-positive Metastatic Breast Cancer

Anticancer research, 2019-07, Vol.39 (7), p.3295-3301

2019

Volltextzugriff (PDF)

Deep mapping of the cytokine release syndrome inflammatory continuum: Comprehensive grade-specific profiling and differentiation from sepsis in patients receiving immune checkpoint therapy

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.12129-12129

2024

Volltextzugriff (PDF)

Statins use and peripheral blood progenitor cells mobilization in patients with multiple myeloma

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e17007-e17007

2012

Volltextzugriff (PDF)

Oncology during the COVID-19 pandemic: challenges, dilemmas and the psychosocial impact on cancer patients

Oncology letters, 2020-07, Vol.20 (1), p.441-447

2020

Volltextzugriff (PDF)

Intraductal patient‐derived xenografts of estrogen receptor α‐positive breast cancer recapitulate the histopathological spectrum and metastatic potential of human lesions

The Journal of pathology, 2019-03, Vol.247 (3), p.287-292

2019

Volltextzugriff (PDF)

Neurotrophic receptor tyrosine kinase family members in secretory and non-secretory breast carcinomas

World journal of clinical oncology, 2022-02, Vol.13 (2), p.135-146

2022

Volltextzugriff (PDF)

Chemotherapy and targeted treatments of breast sarcoma by histologic subtype

Expert review of anticancer therapy, 2021-06, Vol.21 (6), p.591-604

2021

Volltextzugriff (PDF)

Abstract 2993: Intraductal xenografts model ERα-positive invasive lobular carcinoma of the breast

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.2993-2993

2021

Volltextzugriff (PDF)

A pharmacist-led interprofessional medication adherence program improved adherence to oral anticancer therapies: The OpTAT randomized controlled trial

PloS one, 2024-06, Vol.19 (6), p.e0304573

2024

Volltextzugriff (PDF)

Efficacy and safety of the CDK4/6 inhibitor palbociclib during different lines of treatment in patients with advanced stage endocrine sensitive/HER2 negative breast cancer

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e13052-e13052

2018

Volltextzugriff (PDF)

Feasibility of treatment with another CDK4/6 inhibitor after severe ribociclib liver toxicity

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13067-e13067

2023

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(53)
Berichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor

Intraductal xenografts show lobular carcinoma cells rely on their own extracellular matrix and LOXL1

Cytokine storm complicated by cardiogenic shock induced by anti-HER2 therapies

Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer

Pretreatment Thrombocytosis as a Prognostic Factor in Metastatic Breast Cancer

Male breast cancer: a lesser-known battle

Cancer du sein chez l’homme : un combat méconnu

Cancer du sein chez l’homme : un combat méconnu

Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data

The Future of ER+/HER2− Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors

Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies

Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond

Peroxisome Proliferator-Activated Receptor Gamma and Regulations by the Ubiquitin-Proteasome System in Pancreatic Cancer

Plötzlich hörte sie Stimmen

A Systematic Review and Meta-analysis of the Combination of Vinorelbine and Lapatinib in Patients With Her2-positive Metastatic Breast Cancer

Deep mapping of the cytokine release syndrome inflammatory continuum: Comprehensive grade-specific profiling and differentiation from sepsis in patients receiving immune checkpoint therapy

Statins use and peripheral blood progenitor cells mobilization in patients with multiple myeloma

Oncology during the COVID-19 pandemic: challenges, dilemmas and the psychosocial impact on cancer patients

Intraductal patient‐derived xenografts of estrogen receptor α‐positive breast cancer recapitulate the histopathological spectrum and metastatic potential of human lesions

Neurotrophic receptor tyrosine kinase family members in secretory and non-secretory breast carcinomas

Chemotherapy and targeted treatments of breast sarcoma by histologic subtype

Abstract 2993: Intraductal xenografts model ERα-positive invasive lobular carcinoma of the breast

A pharmacist-led interprofessional medication adherence program improved adherence to oral anticancer therapies: The OpTAT randomized controlled trial

Efficacy and safety of the CDK4/6 inhibitor palbociclib during different lines of treatment in patients with advanced stage endocrine sensitive/HER2 negative breast cancer

Feasibility of treatment with another CDK4/6 inhibitor after severe ribociclib liver toxicity

Suchergebnisse filtern